New England Journal of Medicine· 2013Q1

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris et al.

998citations
Q1SCImago
2013year

Short summary

Bardoxolone methyl did not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes and stage 4 chronic kidney disease, and was associated with a higher rate of heart failure events.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Nephrology

NephrologyMedicine